Does Early Administration of Tranexamic Acid Reduce Blood Loss and Perioperative Transfusion Requirement

• Status: Recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

A single-center, prospective randomized study. Consecutive patients presenting with intertrochanteric hip fractures will be treated with tranexamic acid. Treatment will be initiated in the emergency department according to a previously studied protocol for trauma patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mayo Clinic
• Treatments: Tranexamic Acid

Criteria

Inclusion Criteria:

• AO/OTA fracture classification 31A

• Surgically treated with sliding hip screw or cephalomedullary nail (short or long)

• Low energy, isolated injury

• Age greater than 18 years old

Exclusion Criteria:

• Intracapsular hip fractures: AO/OTA fracture classification 31B-C

• Polytrauma patients

• Creatinine clearance less than 30 mL/min

• History of unprovoked VTE and/or recurrent VTE

• Known history of Factor V Leiden, protein C/S deficiency, prothrombin gene mutation, anti-thrombin deficiency, anti-phospholipid antibody syndrome, lupus anticoagulant

• Pregnancy or breastfeeding (pregnancy tests will be performed on all patients of child-bearing potential)

• History of CVA, MI, or VTE within the previous 30 days

• Coronary stent placement within the previous 6 months

• Disseminated intravascular coagulation

• Intracranial hemorrhage